Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Oct 19,2020
Medicilon-Phenomenex Chiral Segmentation Joint Laboratory Unveiling Ceremony
Shanghai, China, October 15, 2020-Shanghai Medicilon and Phenomenex reached a strategic agreement to jointly build a chemistry laboratory for chiral interchange and further enhance the
More
Medicilon-Phenomenex Chiral Segmentation Joint Laboratory Unveiling Ceremony
Oct 17,2020
Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies
Oct 16th, Hainan, China—The 15th Award of competitive and trustworthy listed companies in China was held in Sanya, Hainan. The theme of the forum was
More
Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies
Sep 28,2020
Medicilon will participate 2020 SAPA Annual Conference
Due to the COVID-19 pandemic, the 2020 SAPA Healthcare Investment Forum & Roadshow will be divided in 2 parts.  Part I will be hosted as
More
Medicilon will participate 2020 SAPA Annual Conference
Sep 21,2020
Medicilon is honored as TOP 20 R&D CRO Enterprises in China
Chongqing, September 10, 2020 – 2020 Conference on High Quality Development of Healthcare Industry & the Fifth China Pharmaceutical R&D and Innovation Summit was held
More
Medicilon is honored as TOP 20 R&D CRO Enterprises in China
Sep 05,2020
Online Seminar for Identification and validation of novel therapeutic targets in both breast and kidney cancers
Please reserve for your seat at the below eventbrite link for free. https://www.eventbrite.com/e/novel-therapeutic-targets-in-both-breast-and-kidney-cancers-tickets-119195604261 Hypoxia is associated with resistance towards radiation and chemotherapy. As tumors grow,
More
Online Seminar for Identification and validation of novel therapeutic targets in both breast and kidney cancers
Aug 20,2020
A seminar on preclinical R&D strategic cooperation was held between Medicilon and Yichang Humanwell
Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC (Stock Code: 688202. SH) and Yichang Humanwell
More
A seminar on preclinical R&D strategic cooperation was held between Medicilon and Yichang Humanwell
Aug 13,2020
Medicilon will participate in ACS Fall 2020 Virtual Meeting & Expo
Medicilon will exhibit the ACS Fall 2020 Virtual Meeting & Expo from Aug 17-20.  Please visit https://calendly.com/fywang to schedule a 1-on-1 meeting with our VP
More
Medicilon will participate in ACS Fall 2020 Virtual Meeting & Expo
Aug 13,2020
Application of Solid Dispersion Technology in Formulation Development
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor.
More
Application of Solid Dispersion Technology in Formulation Development
Jun 30,2020
Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research
Chuansha, Shanghai, June 29, 2020. — Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies. Based on previous cooperation
More
Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research
Jun 15,2020
Medicilon will participate 2020 SAPA Healthcare Investment Forum & Roadshow
Due to the COVID-19 pandemic, the 2020 SAPA Healthcare Investment Forum & Roadshow will be divided in 2 parts.  Part I will be hosted as
More
Medicilon will participate 2020 SAPA Healthcare Investment Forum & Roadshow
Jun 04,2020
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Congratualtions to Medicilon's partner, Bio-Thera, on obtaining NMPA's approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of
More
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Jun 01,2020
Medicilon received the "Most Improved in the Science and Technology” award
Led by Dr. CHUN-LIN CHEN, the founder and CEO of Shanghai Medicilon Inc., the entreprenuer team in Medicilon received the "Most Improved in the Science and Technology” award presented by Pudong New Area.
More
Medicilon received the "Most Improved in the Science and Technology” award
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->